These findings support the lysosomal pathway as a critical mechanism by which PCSK9 exerts its effects, aligning with previous studies linking PCSK9 to lysosomal regulation of MHC-I and PD-L1 expression, thereby promoting resistance to tumor immunotherapy [17, 35]. Here, PCSK9 is linked to neoplasm.